Lu AH69593
Alternative Names: Lu-AH69593Latest Information Update: 15 Sep 2025
At a glance
- Originator Lundbeck A/S
- Class Sleep disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Narcolepsy
Most Recent Events
- 13 Jun 2025 Phase-I clinical trials in Narcolepsy in Finland (unspecified route) (CTIS2024-511073-29-00)